RNA, U5A small nuclear 4, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU5A-4P profile across patient tissues and cancer cell-line models. RNU5A-4P expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RNU5A-4P is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, RNU5A-4P RNA expression shows 9,087 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, LUSC, and LSCC as cancer lineages where RNU5A-4P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU5A-4P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU5A-4P survival associations across molecular data types. RNU5A-4P RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU5A-4P RNA expression–survival associations across cancer types. High RNU5A-4P expression shows unfavorable associations in LIHC, UVM, LUSC, READ, STAD and CESC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RNU5A-4P RNA expression.
This table summarizes RNU5A-4P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU5A-4P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU5A-4P shows higher tumor expression in LUSC, BRCA, PRAD, HNSC and COAD. The LUSC box plot shows higher RNU5A-4P RNA expression in tumor versus normal tissue (log2 FC = +0.124, t-test p = .022).
This table shows molecular features associated with RNU5A-4P in patient tissues and cancer cell lines. In patient samples, RNU5A-4P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
